两种方案治疗下呼吸道感染的最小成本分析

A cost-minimization analysis of two therapeutic schemes for the treatment of lower respiratory tract infections

目的探讨两种方案治疗中重度下呼吸道感染的经济学效果。方法51例患者随机分成两组:Ⅰ组25例,给予头孢哌酮/舒巴坦联用左氧氟沙星;Ⅱ组26例,给予亚胺培南/西司他丁。应用最小成本分析法进行经济学评价。结果两种治疗方案有效率分别为48.0%和50.0%(P>0.05),平均疗程分别为9d(QR=5.5)和8.5d(QR=7)(P>0.05)。总成本分别为(9894.97±3477.67)元和(10838.74±3881.75)元。Ⅱ组成本高于I组(P<0.01)。结论从药物经济学角度看,Ⅰ组治疗方案优于Ⅱ组治疗方案。

Objective To study the economical effectiveness of two therapeutic schemes in the treatment of mediated or severe lower respiratory tract infections. Methods Fifty-one patients were randomly divided into two groups： group Ⅰ （ n = 25） treated with combination of eefoperazone/sulbaetam and levofloxaein, and group Ⅱ （n = 26） with imipenem/eilastatin. Data was analyzed using the pharmacoeconomie cost-minimization analysis. Results The effective rates in two groups were 48.0% mad 50.0%, respectively（P 〉 0.05）. The mean therapeutic times were 9 d （QR = 5.5） and 8.5 d （QR = 7） , respectively （P 〉 0.05）. The total treatment cost per patient was higher in group Ⅱ [（10 838.74±3 881.75） yuma] than in group I [（9 874.97±3 477.67）yuan] （P 〈 0.01 ）. Conclusion Considering from the pharmacoeconomics, the scheme in group I is a better one.